Nimodipina Doc Generici (Nimodipine)

Nimodipine, the active ingredient in Nimodipina Doc Generici, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the prevention of cerebral vasospasm after subarachnoid hemorrhage in affected patients.

GNH USA supplies Nimodipina Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable logistics for regulated markets. Products are shipped with full documentation, including certificates of analysis and import permits where required.

Nimodipine is a calcium channel blocker used to manage cerebrovascular complications.

Prevention of cerebral vasospasm after subarachnoid hemorrhage: reduces delayed ischemic neurological deficits by dilating cerebral arteries. Adjunctive therapy in aneurysmal subarachnoid hemorrhage: helps maintain cerebral blood flow during the acute phase. Management of cerebral vasospasm in neurocritical care settings: supports neurological recovery by improving perfusion.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Hypotension: especially in volume‑depleted patients. - Nausea or vomiting: gastrointestinal discomfort. - Dizziness or vertigo: related to blood pressure changes. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: may lead to syncope. - Bradycardia: markedly slow heart rate. - Allergic reactions: rash, pruritus, or angioedema. - Hepatic enzyme elevation: abnormal liver function tests. - Myocardial infarction: rare cardiac events. - Seizures: extremely uncommon but reported.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential complications.

Monitor blood pressure: watch for hypotension, especially in dehydrated individuals. Avoid abrupt discontinuation: taper if long‑term therapy is planned. Use with caution in hepatic impairment: dose adjustment may be required. Avoid concurrent strong CYP3A4 inhibitors: may increase plasma concentrations. Pregnancy: risk unknown; weigh benefits against potential hazards. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Nimodipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): may raise nimodipine levels and precipitate severe hypotension. - Concurrent use with other potent vasodilators: risk of additive blood pressure lowering.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Antihypertensive agents: additive hypotensive effect requires dose adjustment. - Diuretics: can exacerbate volume depletion and hypotension. - NSAIDs: may affect renal perfusion when combined with vasodilation. - Beta‑blockers: monitor heart rate and blood pressure closely.